Shares of Intellia Therapeutics (NTLA) declined following news that Anthropic's AI model discovered a novel enzyme system associated with DNA repeats similar to CRISPR technology. However, the article argues this reaction is temporary and likely overblown, as the findings are early-stage discoveries years away from clinical relevance and do not undermine Intellia's significant progress in gene-editing medicine.
Headquartered in Cambridge, Massachusetts, Intellia has completed Phase 3 trials for lonvoguran ziclumeran (Lonvo-z), a treatment for hereditary angioedema, with U.S. approval and commercial launch expected in the first half of 2027. The company also has nexiguran ziclumeran (Nex-z) in late-stage clinical development for transthyretin amyloidosis (ATTR), targeting a global market expected to reach $16.8 billion by 2030.
Intellia's existing cash resources are projected to fund operations into 2028 without immediate equity dilution, providing financial flexibility to advance its broader pipeline for conditions like hemophilia B and acute myeloid leukemia. Analysts view the stock as attractive following a 30% correction over the last year, with a consensus 'Moderate Buy' rating and a mean price target of $23.18 representing potential upside of 103% from current levels.
📉 Shares dipped due to AI DNA pattern news, viewed as temporary overreaction.
💊 Lonvo-z Phase 3 success expected for U.S. launch in first half of 2027.
📈 Nexiguran ziclumeran targets $16.8B global market by 2030 in late-stage trials.
💰 Cash reserves fund operations through 2028, avoiding immediate equity dilution risk.
📉 Intellia Therapeutics shares declined after Anthropic's AI discovered a DNA pattern reminiscent of CRISPR, but analysts view this as a temporary market overreaction to early-stage research.
💊 Lonvo-z has completed Phase 3 trials for hereditary angioedema, with U.S. approval and commercial launch expected in the first half of 2027.
📈 Nexiguran ziclumeran (Nex-z) is in late-stage clinical development for transthyretin amyloidosis, targeting a global market expected to reach $16.8 billion by 2030.
💰 Intellia's current cash resources are sufficient to fund operations into 2028, eliminating the immediate risk of equity dilution before revenue begins flowing.
🎯 The company has a broad pipeline including early-stage candidates for hemophilia B and acute myeloid leukemia, supported by significant clinical investments.
📊 Analyst consensus is 'Moderate Buy' with a mean price target of $23.18, suggesting 103% upside from current levels based on the company's commercialization catalysts.
Bullish Signals
Nex-z targets $16.8B market by 2030.
Bullish Signals
Intellia Therapeutics has completed Phase 3 trials for Lonvo-z, positioning it for a U.S. approval and commercial launch in the first half of 2027 which serves as a key stock upside catalyst.
The company's Nex-z candidate targets transthyretin amyloidosis in a global market expected to swell to $16.8 billion by 2030, offering significant future revenue potential.
Intellia possesses sufficient cash resources to fund operations into 2028 without immediate equity dilution, providing financial flexibility to pursue its deeper clinical pipeline.
Analysts maintain a consensus 'Moderate Buy' rating with a mean price target of $23.18, implying substantial upside potential following the recent stock correction.
CRISPR Therapeutics AG (NASDAQ: CRSP) General Counsel James Kasinger sold 10,400 shares of the company's stock on September 22nd at an average price of $60.24 per share. The transaction totaled approximately $626,496 and resulted in a 9.89% decrease in his personal ownership, leaving him with 94,784 shares valued at roughly $5.71 million. This insider sale was disclosed via a document filed with the Securities & Exchange Commission.
The company continues to trade with a market capitalization of $5.39 billion and a price-to-earnings ratio of -11.70, reflecting its pre-profit status in the biotechnology sector. Its stock has fluctuated between a one-year low of $44.12 and a high of $78.48, currently trading above its 50-day moving average of $53.63 but below its 200-day average of $52.75.
Financially, CRISPR Therapeutics reported quarterly earnings of -$0.94 per share and revenue of $10.18 million for the quarter ended June 30th. Analyst consensus predicts negative earnings of -$4.47 for the current year. The stock holds a consensus price target of $67.94, with ratings ranging from 'Strong Buy' to 'Sell' among major investment banks.
Institutional ownership remains significant at 69.20%, with several hedge funds increasing their positions in recent quarters. Key assets include Casgevy (exa-cel), a gene-edited cell therapy approved for sickle cell disease and beta thalassemia, developed in collaboration with Vertex Pharmaceuticals.
📉 General Counsel sold 10,400 shares for $626,496 on Sept 22.
💰 Stock trades at $55.70 with a $5.39 billion market cap.
📉 Q2 EPS loss was -$0.94; analysts predict -$4.47 annual earnings.
🏥 Casgevy is approved for sickle cell and beta thalassemia.
📈 Consensus price target is $67.94 with a 'Moderate Buy' rating.
📉 General Counsel James Kasinger sold 10,400 shares of CRSP on September 22nd for a total value of $626,496.
📊 The insider sale represented a 9.89% reduction in his personal holdings, leaving him with approximately 94,784 shares.
💰 Following the transaction, Kasinger's remaining stake is valued at roughly $5.71 million based on current market prices.
📈 CRISPR Therapeutics stock opened at $55.70 and trades with a market cap of $5.39 billion.
💸 The company reported quarterly revenue of $10.18 million and an EPS loss of -$0.94 for the quarter ended June 30th.
📉 Analysts predict negative earnings of -$4.47 per share for the current fiscal year.
🏥 CRISPR Therapeutics' lead product, Casgevy (exa-cel), is approved in several markets for treating sickle cell disease and beta thalassemia.
🤝 The Casgevy therapy was developed in collaboration with Vertex Pharmaceuticals using CRISPR/Cas9 gene editing technology.
📊 Institutional investors own 69.20% of the company's outstanding shares.
📈 Hedge fund IFP Advisors Inc boosted its position by 29.9% in the 4th quarter, now holding 1,250 shares.
📈 Versant Capital Management Inc increased its holdings by 175.1% in the second quarter.
📈 D.A. Davidson & CO. grew its position by 5.9% in the first quarter.
📈 Kestra Advisory Services LLC expanded its stake by 2.0% in the first quarter.
🏦 Goldman Sachs maintains a 'neutral' rating with a $55.00 price target on CRSP shares.
🏦 UBS Group set an $80.00 price target on the stock in a recent research report.
🏦 Citigroup restated its rating to 'market outperform' on August 25th.
🏦 HC Wainwright reaffirmed a 'buy' rating on CRSP shares as of August 31st.
📊 The stock currently holds an average analyst rating of 'Moderate Buy' with a consensus price target of $67.94.
📉 Weiss Ratings issued a 'sell (d-)' rating on the company in July.
📉 The company has a negative return on equity of -24.39% and a negative net margin of -3,368.72%.
📈 CRSP has a beta of 1.76, indicating higher volatility than the broader market.
Bullish Signals
Institutional ownership stands at 69.20%.
Hedge funds raised stakes significantly.
Analysts maintain bullish or neutral ratings.
Consensus price target is $67.94.
Casgevy is an approved commercial asset.
Risk Factors
General Counsel sold nearly 10% of shares.
Analysts predict negative earnings of -$4.47 this year.
Weiss Ratings issued a 'sell (d-)' rating.
High beta of 1.76 exposes to volatility.
Bullish Signals
Institutional ownership remains strong at 69.20%, indicating continued confidence from major investors.
Several hedge funds increased their positions recently, with IFP Advisors Inc boosting holdings by 29.9% and Versant Capital Management Inc increasing stakes by 175.1%.
Major analysts maintain bullish or neutral stances, including HC Wainwright's 'buy' rating and Citigroup's 'market outperform' rating.
The consensus price target of $67.94 suggests potential upside from current trading levels.
Casgevy (exa-cel) is an approved gene-edited therapy for serious conditions like sickle cell disease, representing a significant commercial asset.
Risk Factors
General Counsel James Kasinger sold nearly 10% of his shares in a single transaction, which can signal insider caution.
Analysts predict continued negative earnings of -$4.47 for the current year, highlighting financial pressure.
Weiss Ratings issued a 'sell (d-)' rating, adding to mixed analyst sentiment regarding the stock's near-term prospects.
The company has a high beta of 1.76, exposing shareholders to significant market volatility.
The article compares CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX), highlighting their distinct positions in the gene-editing space. CRISPR is characterized as a research-focused pioneer that recently secured its first product approval for CASGEVY, treating sickle cell disease and beta thalassemia. However, the company faces significant financial headwinds, reporting revenue of nearly $3.5 million for FY 2025—a 90% decrease from the prior year due to the cessation of large one-time milestone payments.
CRISPR Therapeutics reported a net loss of approximately $581.6 million in FY 2025 as it continues heavy investment in its research pipeline. While the company maintains a conservative debt-to-equity ratio of roughly 0.2x and a strong current ratio of 13.3x, its free cash flow was negative at $345.9 million. The article notes that CRISPR relies heavily on Vertex for the commercial success and manufacturing of CASGEVY, raising concerns about potential capital dilution if further funding is required.
Beyond financial metrics, CRISPR faces specific risks including a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core gene-editing technology. The article also cites that The Motley Fool's Stock Advisor team did not include CRISPR Therapeutics in their list of top 10 stocks to buy now, contrasting this with Vertex Pharmaceuticals, which was recommended for its established commercial success and diversified portfolio.
📉 Revenue dropped nearly 90% to $3.5M as milestone payments ceased in FY 2025.
💸 Net loss reached $581.6M with negative free cash flow of $345.9M for the year.
⚖️ Maintains conservative 0.2x debt-to-equity ratio while relying on Vertex for CASGEVY commercialization.
⚠️ Facing patent infringement lawsuit from ToolGen regarding core technology in late 2025.
🚀 Achieved product approval and expanding CASGEVY to younger patients despite financial losses.
📉 CRISPR Therapeutics revenue dropped nearly 90% to $3.5 million in FY 2025 as one-time milestone payments ceased.
💸 The company reported a net loss of approximately $581.6 million and negative free cash flow of $345.9 million for the year.
⚖️ CRISPR maintains a conservative debt-to-equity ratio of 0.2x but relies on Vertex for CASGEVY commercialization.
⚠️ The company is involved in a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core technology.
📉 Analysts from The Motley Fool's Stock Advisor did not include CRISPR Therapeutics in their top 10 stocks list for the current period.
🚀 Despite financial losses, CRISPR has achieved a product approval and is expanding CASGEVY to younger patients.
Bullish Signals
CRISPR Therapeutics received first approval for CASGEVY treating sickle cell disease.
Debt-to-equity ratio is 0.2x with strong current ratio of 13.3x.
Gene-editing therapy expands patient reach to younger demographics successfully.
Risk Factors
Revenue fell ~90% to $3.5M in FY 2025.
Net loss reached $581.6M with negative FCF.
Facing patent infringement lawsuit from ToolGen.
Future profitability uncertain due to heavy losses.
Bullish Signals
CRISPR Therapeutics recently achieved its first product approval for CASGEVY, treating sickle cell disease and transfusion-dependent beta thalassemia.
The company maintains a conservative debt-to-equity ratio of roughly 0.2x and a strong current ratio of 13.3x, indicating robust short-term liquidity.
CRISPR has built a gene-editing therapy that is commercially successful and expanding its patient reach to younger demographics.
Risk Factors
Revenue fell by approximately 90% to $3.5 million in FY 2025 as the company transitioned from one-time milestone payments to recurring sales.
The company reported a substantial net loss of roughly $581.6 million and negative free cash flow of $345.9 million during the fiscal year.
The company is currently involved in a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core gene-editing technology.
There is no guarantee that CRISPR will achieve future profitability given its ongoing operating losses and heavy research investments.
Drug approvalFinancial outlookAI-generated analysis
CRISPR Therapeutics (CRSP) stock has underperformed over the past year, trading 48% below the average Wall Street price target of $87.56 despite holding the only approved CRISPR-based gene therapy, CASGEVY. The company recently closed a $600 million convertible note offering, boosting its pro forma cash to approximately $2.56 billion, which provides significant runway for R&D without immediate dilution.
Commercial performance shows mixed signals with Q2 2026 revenue surging 151% year-over-year to $76 million, yet full-year 2025 revenue was only $3.51 million due to a lapsed cost-deferral arrangement with partner Vertex. Q4 2025 revenue collapsed by 97.5% to $864K, and Q1 2026 missed estimates by 65.73%, leading to heavy cash burn of $581.6 million in 2025.
Analyst sentiment is notably bullish, with Piper Sandler analyst Edward Tenthoff maintaining an Overweight rating and a Street-high price target of $110, implying roughly 86% upside. Tenthoff models 2026 CASGEVY revenue around $300 million based on approximately 150 patient starts, significantly higher than the consensus estimate of $40.83 million, driven by potential pediatric expansion and FDA clearance for children ages 5-11.
The company's pipeline includes CTX310 Phase 1b durability data due at the ESC Congress and readouts for zugo-cel in autoimmune and B-cell lymphoma indications. While CRSP is the only peer with an approved commercial product generating revenue, it trades at a discount compared to rivals like Intellia Therapeutics and Beam Therapeutics, offering a favorable risk-reward profile if CASGEVY's commercial ramp accelerates.
📉 CRSP shares down 4.94% over past year, trading 48% below consensus target.
💰 Raised $600M convertible note; pro forma cash reaches roughly $2.56 billion.
Piper Sandler analyst Edward Tenthoff maintains a Street-high price target of $110, implying roughly 86% upside from current levels.
Analyst consensus models 2026 CASGEVY revenue at $300 million based on approximately 150 patient starts, significantly higher than the Street estimate.
The company has received FDA clearance for children ages 5-11 via priority review vouchers, opening a fresh patient cohort for CASGEVY.
EPS revisions have skewed upward with 12 upward revisions versus only 3 down in the trailing 30 days for FY2026.
CRSP is the only name in its peer group with an approved commercial product generating revenue, making it the least discounted of the group.
Risk Factors
Full-year 2025 revenue was only $3.51 million due to a lapsed cost-deferral arrangement with partner Vertex.
The company reported a heavy cash burn with a net loss of $581.6 million in 2025 despite Q2 revenue beats.
Q1 2026 revenue missed estimates by 65.73%, causing the market to treat CRSP as a story stock in limbo.
The commercial ramp for CASGEVY remains unproven, with markets awaiting sustained growth beyond partner-reported figures.
CRISPR Therapeutics AG (NASDAQ:CRSP) director Ali Behbahani sold 13,679 shares on September 17th at an average price of $57.09, reducing his position by 45.12% to a remaining holding of 16,637 shares valued at approximately $949,806. This insider transaction was disclosed in a legal filing with the Securities & Exchange Commission.
The company reported quarterly earnings for the quarter ended June 30th, posting a loss of $0.94 per share on revenue of $10.18 million. CRISPR Therapeutics has a market capitalization of $5.64 billion and trades with a price-to-earnings ratio of -12.25. Analysts forecast an average annual EPS of -$4.47 for the current fiscal year.
Wall Street sentiment remains mixed, with Morgan Stanley maintaining an 'equal weight' rating at $60.00 and Goldman Sachs reiterating a 'neutral' stance at $55.00. However, MarketBeat aggregates analyst ratings to a 'Moderate Buy' with an average price target of $67.94. Institutional ownership is significant, with major funds like Capital International Investors and Geode Capital Management increasing their stakes in the fourth quarter.
📉 Director Ali Behbahani sold 13,679 shares worth $780,934 on September 17th.
📊 Q2 earnings showed -$0.94 EPS on $10.18 million revenue as of June 30th.
🏦 Capital International Investors increased holdings by 4.3% to own 5,892,745 shares.
🔬 Casgevy is approved in several markets for sickle cell disease and beta thalassemia.
📉 Director Ali Behbahani sold 13,679 shares of CRSP on September 17th for a total value of $780,934.11.
📊 The company reported Q2 earnings of -$0.94 EPS on revenue of $10.18 million as of June 30th.
🏦 Capital International Investors increased its CRSP holdings by 4.3% in the fourth quarter to own 5,892,745 shares.
📈 Geode Capital Management LLC raised its stake by 5.0% in the fourth quarter, adding 108,053 shares.
🏛 Norges Bank and Swiss National Bank established or increased new positions in CRSP during recent quarters.
💰 The company's market cap stands at $5.64 billion with a debt-to-equity ratio of 0.34.
📉 Analysts forecast an average EPS of -$4.47 for the current fiscal year following Q2 results.
🎯 Morgan Stanley set a $60.00 price objective while Goldman Sachs issued a $55.00 target.
🔬 CRISPR Therapeutics' lead product Casgevy is approved in several markets for sickle cell disease and beta thalassemia.
Bullish Signals
Major institutions increased positions in Q4.
Risk Factors
Director Ali Behbahani sold 13,679 shares, reducing position by 45.12%.
Analysts forecast continued losses with average expected EPS of -$4.47.
Bullish Signals
Major institutional investors including Capital International Investors, Geode Capital Management LLC, Norges Bank, and Swiss National Bank increased or established new positions in the fourth quarter.
MarketBeat aggregates analyst ratings to a 'Moderate Buy' with an average price target of $67.94, suggesting potential upside from current levels.
The company's lead product Casgevy is approved in several markets for treating sickle cell disease and transfusion-dependent beta thalassemia.
Risk Factors
Director Ali Behbahani reduced his position by 45.12% through a significant sale of 13,679 shares on September 17th.
Analysts forecast continued losses with an average expected EPS of -$4.47 for the current fiscal year.
As of September 19, 2026, CRISPR Therapeutics AG (CRSP) trades at $56.56, with Wall Street analysts maintaining a consensus price target of $80.00, implying approximately 41.4% upside potential. The technical indicators show the stock trading above its 50-day average of $53.03 with an RSI of 46, indicating neutral momentum.
Insider activity reveals a net buying position, with insiders purchasing $52.7 million in stock against $18.5 million in sales, signaling management confidence in the company's future prospects. Analysts forecast significant revenue growth of 283% for the coming year to reach $61.2 million, driven by the company's pipeline and market potential.
Despite the bullish insider sentiment and revenue forecasts, CRSP faces valuation risks with a price-to-sales ratio of 376.97, significantly higher than the sector median, while remaining unprofitable with negative EPS. Historical performance shows that a $10,000 investment in October 2016 would be worth roughly $40,142 today, outperforming the S&P 500 benchmark of $35,546 over the same period.
CleaRank's Monte Carlo simulations project a base-case price near $85.62 by 2030, representing a 1.5x return from current levels, though the model also highlights a downside path ending near $23.77 due to the stock's high volatility and lack of dividends.
📈 CRSP trades at $56.56 with $80.00 consensus target implying 41.4% upside.
💼 Insiders net bought $52.7M in shares versus $18.5M sold recently.
📊 Revenue forecasted to surge 283% next year to $61.2M on pipeline.
⚠️ CRSP carries high 376.97 price-to-sales ratio and remains unprofitable with negative EPS.
🔮 Simulations project base-case $85.62 by 2030 but warn of high volatility.
📈 CRISPR Therapeutics AG (CRSP) trades at $56.56 with a Wall Street consensus target of $80.00, suggesting 41.4% upside potential.
💼 Insiders have executed a net buying position, purchasing $52.7 million in shares against only $18.5 million in sales.
📊 Analysts forecast next year's revenue to surge by 283% to $61.2 million driven by the company's pipeline.
⚠️ The company carries a high price-to-sales ratio of 376.97 and remains unprofitable with negative EPS.
📉 Historical consistency is mixed, with only the latest quarter showing an EPS beat after previous mixed results.
🔮 CleaRank simulations project a base-case price of $85.62 by 2030 but warn of high volatility and a downside path to $23.77.
Bullish Signals
Insiders bought $52.7M stock vs $18.5M sales.
Revenue forecast grows 283% to $61.2M.
Risk Factors
P/S ratio of 376.97 exceeds sector median.
Negative EPS risks high growth expectations.
Bullish Signals
Insiders have purchased $52.7 million worth of stock against $18.5 million in sales, indicating strong management confidence.
Analysts forecast next year's revenue to grow by 283% to $61.2 million, driven by the company's pipeline and market potential.
Risk Factors
The company's price-to-sales ratio of 376.97 is significantly higher than the sector median, posing a valuation risk.
EPS remains negative, creating a risk if the high growth expectations are not met to justify the premium valuation.
CRISPR Therapeutics is preparing for its initial public offering (IPO), having registered an S-1 form with the U.S. Securities and Exchange Commission. The company plans to price between 4 million and 5.4 million shares in a range of $15 to $17 per share, valuing the offering at up to approximately $92 million upon listing on the Nasdaq under the symbol CRSP.
The proceeds from the IPO will primarily fund the advancement of its hemoglobinopathy programs, progress additional pipeline candidates, and optimize its CRISPR/Cas9 gene editing platform. The company intends to use the remainder for working capital and general corporate purposes to support its strategic growth initiatives in the biopharmaceutical sector.
CRISPR Therapeutics is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics for rare and common diseases. Through strategic partnerships, including a joint venture with Bayer AG and a collaboration with Vertex Pharmaceuticals Incorporated, the company has secured over $400 million in funding to accelerate development and access distinctive capabilities in specific disease areas.
📈 CRSP IPO priced $15-$17/share with up to $92M valuation.
🔬 Developing CRISPR/Cas9 therapeutics for rare and common diseases.
💰 Strategic partnerships provide over $400M in funding.
📊 Proceeds advance hemoglobinopathy programs and optimize gene editing platform.
🏢 Listing on Nasdaq under symbol CRSP.
📈 CRISPR Therapeutics is preparing for an IPO priced between $15 and $17 per share with a valuation of up to nearly $92 million.
🔬 The company is focused on developing CRISPR/Cas9-based therapeutics to treat rare and common diseases by altering genomic DNA sequences.
💰 Strategic partnerships with Bayer AG and Vertex Pharmaceuticals Incorporated provide over $400 million in funding for program development.
📊 The IPO proceeds will be used to advance hemoglobinopathy programs, progress pipeline candidates, and optimize the gene editing platform.
🏢 CRISPR Therapeutics intends to list its shares on the Nasdaq under the symbol CRSP following the S-1 registration.
Bullish Signals
Secured $400M funding via Bayer and Vertex partnerships.
Positions as CRISPR/Cas9 leader with experienced team.
Bullish Signals
CRISPR Therapeutics has secured over $400 million in funding through strategic partnerships with Bayer AG and Vertex Pharmaceuticals Incorporated to accelerate development.
The company is positioning itself as a leader in the development of CRISPR/Cas9-based therapeutics with an experienced team in drug discovery and clinical development.
CRISPR Therapeutics (CRSP) stock has experienced a short-term recovery, though long-term investors remain at a loss following a roughly 52.7% decline over the past five years. Current valuation metrics suggest the stock is priced toward an expensive reading rather than representing a clear bargain, trading at a Price-to-Book ratio of approximately 3.2x.
This premium multiple sits above the broader biotech industry average of 2.5x but remains below a peer group average of 7.0x. The elevated valuation reflects investor confidence in the company's drug pipeline following fresh Phase 1a data for CTX310 presented at the ESC Congress in 2026, which supports the platform's potential despite ongoing clinical and regulatory risks.
The article concludes that while the current share price embeds expectations for successful development and commercialization of the gene editing platform, the critical question remains whether the pipeline can translate into durable cash flows quickly enough to justify this richer multiple amidst early-stage biotech uncertainty.
📉 CRSP shares down 52.7% over five years despite recent gains.
💰 CRSP trades at 3.2x book value, below peer average of 7.0x.
🧬 Phase 1a CTX310 data at ESC Congress 2026 bolsters confidence.
⚠️ High valuation assumes successful development and future cash flow.
🔬 CRSP faces clinical risks in transitioning to revenue streams.
📉 CRISPR Therapeutics shares are down approximately 52.7% over the last five years, leaving long-term holders underwater despite recent short-term gains.
💰 The company trades at a Price-to-Book ratio of about 3.2x, which is higher than the broader biotech industry average of 2.5x but lower than peer group averages around 7.0x.
🧬 Fresh Phase 1a clinical data for CTX310 presented at the ESC Congress in 2026 has bolstered confidence in the company's gene editing drug pipeline.
⚠️ Investors are paying a premium that assumes successful development and commercialization, embedding high expectations for future cash flow generation.
🔬 The stock faces significant clinical and regulatory risks associated with transitioning an early-stage biotech pipeline into sustained revenue streams.
Bullish Signals
Fresh Phase 1a data for CTX310 presented at the ESC Congress in 2026 supports confidence in the company's gene editing drug pipeline.
The stock trades at a Price-to-Book ratio of approximately 3.2x, which is below the peer group average of 7.0x, suggesting it is not the most highly valued within its specific peer set.
Risk Factors
Long-term investors are still sitting on a large loss after the share price declined about 52.7% over the past five years.
The company screens as overvalued on market multiples with a P/B of 3.2x, which is above the wider biotech industry average of roughly 2.5x.
Significant clinical and regulatory risks remain around turning the early-stage pipeline into sustained cash flows.
CRISPR Therapeutics reported strong second-quarter 2026 financial results, driven by significant growth in its blockbuster gene-edited therapy CASGEVY. The company generated $76 million in revenue for the quarter, representing a 78% increase from the previous quarter and a 151% year-over-year surge. This momentum was bolstered by the FDA's recent approval of CASGEVY for children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia, expanding the eligible patient population to approximately 5,500 individuals.
Beyond its commercial success, CRISPR Therapeutics advanced multiple in vivo and ex vivo pipeline programs. The company initiated Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency using its proprietary SyNTase editing platform. Additionally, development continues on CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia, with a late-breaking abstract accepted for presentation at the European Society of Cardiology Congress in August 2026.
Financially, the company strengthened its balance sheet with $2.36 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, up from $1.98 billion a year prior. This increase was primarily fueled by $585 million in proceeds from convertible senior notes issued in March 2026. While the company reported a net loss of $91.2 million for the quarter, this represents a substantial improvement compared to the $208.5 million loss recorded in the same period last year, reflecting improved operational efficiency and revenue recognition.
The press release also highlighted progress in its autoimmune and immuno-oncology portfolios, including the allogeneic CAR-T cell therapy zugo-cel and siRNA-based programs like CTX611 for thromboembolic diseases. Strategic collaborations with Vertex Pharmaceuticals and Sirius Therapeutics continue to support development and commercialization efforts globally, positioning CRISPR Therapeutics as a diversified leader in gene editing technologies.
📈 CASGEVY revenue hit $76M in Q2 2026, up 151% year-over-year.
✅ FDA approved CASGEVY for sickle cell disease in children aged 2+.
💰 Cash and securities totaled $2.36 billion as of June 30, 2026.
📉 Net loss narrowed to $91.2 million in Q2 2026 from $208.5M.
🤝 Vertex collaboration leads global CASGEVY development on a 60/40 basis.
📈 CASGEVY revenue reached $76 million in Q2 2026, marking a 78% quarter-over-quarter and 151% year-over-year increase.
✅ FDA approved CASGEVY for children aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, expanding the addressable market.
🧬 Phase 1 clinical trials initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).
💰 Cash, cash equivalents, and marketable securities totaled $2.36 billion as of June 30, 2026.
📉 Net loss narrowed to $91.2 million in Q2 2026 from $208.5 million in the same quarter last year.
🔬 CTX310 (ANGPTL3) development continues in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia.
🤝 Collaboration with Vertex Pharmaceuticals leads global development and commercialization of CASGEVY on a 60/40 basis.
🧬 Zugo-cel (CTX112) advancing in Phase 1 trials for autoimmune diseases including lupus, sclerosis, and multiple sclerosis.
🩸 CTX611 (FXI inhibitor) advancing through Phase 2 trials for thromboembolic disorders with potential broad indications.
📈 Analysts maintained or upgraded ratings, with Citi raising its price target to $88 citing CASGEVY momentum.
Bullish Signals
Q2 revenue surged $76M, up 78% QoQ and 151% YoY.
FDA approval expands eligible pediatric population to ~5,500 children.
$2.36B cash position funds pipeline development and commercialization.
Net loss decreased to $91.2M from $208.5M prior year.
Phase 1 trials for CTX340/CTX460 expand SyNTase technology.
Risk Factors
Net loss of $91.2 million this quarter.
Global reimbursement efforts for CASGEVY remain ongoing.
Early Phase 1 trials for CTX340 and CTX460 pending.
Bullish Signals
CASGEVY revenue surged to $76 million in Q2 2026, driven by a 78% quarter-over-quarter and 151% year-over-year growth.
FDA approval for CASGEVY in children as young as two years old significantly expands the eligible patient population to approximately 5,500 individuals.
Strong cash position of $2.36 billion provides ample liquidity to fund pipeline development and commercialization efforts.
Net loss decreased substantially to $91.2 million from $208.5 million in the prior year quarter, indicating improving financial trajectory.
Initiation of Phase 1 trials for CTX340 and CTX460 demonstrates successful expansion into new therapeutic areas using proprietary SyNTase technology.
CTX310 program continues to advance with a late-breaking abstract accepted for presentation at the European Society of Cardiology Congress.
Strategic collaborations with Vertex and Sirius Therapeutics provide shared resources and global commercialization reach.
Risk Factors
Company reported a net loss of $91.2 million for the quarter, though this is an improvement over the previous year.
Ongoing efforts to secure sustainable reimbursement globally for CASGEVY remain underway in various markets.
Clinical trials for investigational candidates like CTX340 and CTX460 are still in early Phase 1 stages with long-term outcomes yet to be determined.
CRISPR Therapeutics reported financial results and a business update for the second quarter ended June 30, 2026. CEO Samarth Kulkarni highlighted strong execution across the portfolio, noting continued momentum for CASGEVY following FDA approval for children as young as two years old. The company also expanded its in vivo pipeline by initiating Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency.
The press release details the company's diversified portfolio, including its strategic collaboration with Vertex Pharmaceuticals for CASGEVY, where Vertex leads global development and commercialization while profits are shared on a 60/40 basis. CRISPR Therapeutics is advancing proprietary in vivo liver editing programs using its SyNTase technology to treat cardiovascular diseases like familial hypercholesterolemia and hypertension.
Additionally, the company is developing Zugocabtagene geleucel (zugo-cel), an allogeneic CAR T cell therapy for autoimmune diseases and hematologic malignancies. A collaboration with Sirius Therapeutics focuses on siRNA-based programs, specifically CTX611, a long-acting inhibitor of coagulation factor XI intended to provide anticoagulant effects with reduced bleeding risk.
📅 CRISPR Therapeutics reported Q2 2026 results on August 3, 2026.
✅ CASGEVY FDA approved for children as young as 2 years old.
🤝 Vertex leads global development under a 60/40 profit-sharing agreement.
🧬 Phase 1 trials initiated for CTX340 and CTX460 therapies.
💉 Advancing in vivo liver editing using proprietary SyNTase technology.
📅 CRISPR Therapeutics reported Q2 2026 financial results and provided a business update on August 3, 2026.
✅ CASGEVY momentum continues with FDA approval extended to children as young as 2 years old for sickle cell disease and transfusion-dependent beta thalassemia.
🧬 Phase 1 clinical trials were initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).
🤝 Vertex Pharmaceuticals leads global development and commercialization of CASGEVY under a 60/40 profit-sharing agreement.
💉 CRISPR Therapeutics is advancing in vivo liver editing programs using its proprietary SyNTase technology for cardiovascular indications.
🧬 Zugocabtagene geleucel (zugo-cel) advances as an allogeneic CAR T cell therapy for autoimmune diseases and oncology.
🩸 Collaboration with Sirius Therapeutics develops CTX611, a long-acting siRNA targeting coagulation factor XI.
Bullish Signals
CASGEVY expands to pediatric patients as young as two years old.
Phase 1 trials initiated for new programs CTX340 and CTX460.
Strategic collaborations with Vertex and Sirius Therapeutics diversify pipeline.
Bullish Signals
CASGEVY demonstrates strong market momentum with regulatory expansion to include pediatric patients as young as two years old.
The company successfully initiated Phase 1 clinical trials for two new in vivo programs, CTX340 and CTX460, expanding its therapeutic reach.
Strategic collaborations with Vertex and Sirius Therapeutics provide a diversified pipeline spanning gene editing and siRNA technologies.
CRISPR Therapeutics AG (NASDAQ: CRSP) is highlighted as a biotech stock with significant upside potential, ranking 8th on a list of 12 top picks compiled by Insider Monkey as of January 15, 2025. The article notes that while 2024 was challenging for the sector, experts like Johan Hueffer of Novo Holdings and John Flood of Goldman Sachs believe conditions are improving. Hueffer observed that capital raising difficulties have eased in recent quarters, while Flood pointed out that biotech stocks offer an "option-like structure" due to their sensitivity to interest rates and reliance on future profits. This sensitivity is particularly relevant following the Federal Reserve's rate cuts since September, which reduced the benchmark borrowing rate to a 4.25%-4.5% target range by January 8, 2025, with market expectations for further cuts in 2025 adjusted downward.
The company, headquartered in Zug, Switzerland, utilizes its proprietary CRISPR/Cas9 platform to develop gene-based medicines for serious diseases such as oncology, rare diseases, and regenerative medicine. A major catalyst for CRSP is the FDA approval and global launch of CASGEVY, a gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older, which has received regulatory clearance in markets including Canada, Switzerland, Great Britain, and the European Union. As of September 30, 2024, CRISPR Therapeutics maintains a robust financial position with approximately $1.9 billion in cash, cash equivalents, and marketable securities, providing the liquidity needed to advance its clinical trial portfolio across autoimmune, diabetes, and cardiovascular indications.
Despite these positive fundamentals, Goldman Sachs data indicates that the biotechnology sector remains under-owned by hedge funds, ranking in the 13th percentile for long/short positioning over the past year and the 4th percentile over the last five years. Insider Monkey suggests that investors can potentially outperform the market by imitating top hedge fund picks, citing their quarterly newsletter strategy which has returned 275% since May 2014, significantly beating its benchmark. However, the article concludes with a caveat that while CRSP holds promise, the authors maintain greater conviction in AI stocks for delivering higher returns over shorter timeframes, directing readers to separate reports on AI investments and dividend stocks from companies like Nike, McDonald's, and JPMorgan Chase.
📈 JPMorgan and Novo see biotech poised for upside after 2024.
📉 Fed lowered rates to 4.25%-4.5% range in early January.
📊 Biotech remains under-owned by hedge funds at 13th percentile.
🧬 CRISPR Therapeutics holds $1.9B cash and ranks 8th for upside.
📈 JPMorgan and Novo Holdings view biotech stocks as poised for considerable upside following a challenging 2024 and improving capital-raising trends.
🏦 Goldman Sachs highlights that biotech offers an "option-like structure" with significant potential due to sensitivity to the Federal Reserve's recent rate cuts.
📉 The Fed reduced its benchmark borrowing rate to a 4.25%-4.5% range in early January, though it lowered its outlook for future rate cuts in 2025.
📊 Goldman Sachs data indicates the biotech sector remains under-owned by hedge funds, ranking in the 13th percentile for long/short positioning over the past year.
🧬 CRISPR Therapeutics AG (CRSP) utilizes a proprietary CRISPR/Cas9 platform to develop gene-based medicines for serious diseases like oncology and rare disorders.
✅ The FDA approved CASGEVY, a gene therapy for sickle cell disease and beta-thalassemia, which has gained regulatory approval in multiple countries including the EU and UK.
💰 As of September 30, 2024, CRISPR Therapeutics holds a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities.
🔬 The company is strategically advancing its clinical trial portfolio across autoimmune, diabetes, oncology, and cardiovascular indications for 2025 expansion.
🏆 CRSP ranks 8th on a list of 12 biotech stocks selected for having the highest analyst upside potential as of January 15, 2025.
🤖 The article notes that while CRSP has strong potential, the authors maintain greater conviction in AI stocks for delivering higher returns within a shorter timeframe.
Bullish Signals
FDA approved CASGEVY for ages 12+.
Regulatory approvals advancing in Canada, UK, EU.
Gene therapy launches for sickle cell disease.
Bullish Signals
CRISPR Therapeutics AG (CRSP) has received FDA approval and launched CASGEVY, a gene therapy for sickle cell disease and beta-thalassemia in patients 12 years and older, creating considerable momentum with regulatory approvals underway in Canada, Switzerland, Great Britain, the European Union, and others.
Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG by 5.3% during the first quarter, selling 104,236 shares and holding approximately 1.85 million shares valued at $88.19 million. The position represents about 1.2% of Amova's total holdings and ranks as its 26th largest position. Several other major institutional investors have adjusted their positions in the stock recently, with GSK plc initiating a new stake worth roughly $168.89 million in the fourth quarter.
Orbis Allan Gray Ltd increased its CRISPR Therapeutics holding by 76.9% in the second quarter to own 2.76 million shares valued at $134.47 million, while State Street Corp lifted its position by 35.6% to hold 3.27 million shares worth $159.08 million. ARK Investment Management LLC grew its stake by 7.5% in the fourth quarter, now owning over 10.5 million shares valued at $551.78 million, and Norges Bank acquired a new position valued at approximately $25.71 million.
Insider Naimish Patel sold 3,786 shares for a total value of $210,577 to cover tax withholding obligations related to the vesting of equity awards, reducing his personal holding by 16.36%. Following this transaction, he retains 19,357 shares valued at approximately $1.08 million. Company insiders collectively own 5.20% of CRISPR Therapeutics stock. The article also notes recent quarterly earnings results showing a loss per share of $1.28 and revenue of $1.46 million for the quarter.
CRISPR Therapeutics is a biopharmaceutical company developing gene-editing therapies using its proprietary CRISPR/Cas9 platform to treat serious diseases through ex vivo and in vivo applications. Its lead program, CTX001, is an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent beta-thalassemia in collaboration with Vertex Pharmaceuticals. The company currently has a market capitalization of $4.53 billion and a negative price-to-earnings ratio of -7.55.
📉 Amova Asset Management trimmed stake by 5.3% to $88.19 million value.
📈 ARK Investment holds largest position with 10.52 million shares worth $551.78 million.
💰 Company insiders collectively own 5.20% of CRISPR Therapeutics stock.
📊 Q1 loss per share was $1.28 on revenue of $1.46 million.
🧬 Lead program CTX001 treats sickle cell disease and beta-thalassemia with Vertex.
📉 Amova Asset Management Americas Inc. trimmed its CRISPR Therapeutics stake by 5.3% in Q1, selling 104,236 shares and retaining a position worth $88.19 million.
📈 GSK plc acquired a new position in CRISPR Therapeutics in Q4 valued at approximately $168.89 million.
📈 Orbis Allan Gray Ltd raised its stake by 76.9% in Q2, now owning 2.76 million shares valued at $134.47 million.
📈 State Street Corp increased its holdings by 35.6% in Q2 to own 3.27 million shares worth $159.08 million.
📈 ARK Investment Management LLC grew its position by 7.5% in Q4, holding 10.52 million shares valued at $551.78 million.
🏦 Norges Bank purchased a new stake in CRISPR Therapeutics in Q4 valued at approximately $25.71 million.
👤 Insider Naimish Patel sold 3,786 shares for $210,577 to cover tax withholding obligations related to equity vesting.
💰 Company insiders collectively own 5.20% of CRISPR Therapeutics stock following the recent insider sale.
📊 The company reported a loss per share of $1.28 and revenue of $1.46 million for the quarter ending March 31st.
🧬 CRISPR Therapeutics focuses on developing gene-editing therapies using its CRISPR/Cas9 platform for serious diseases.
💉 Its lead program CTX001 is an ex vivo edited cell therapy designed to treat sickle cell disease and beta-thalassemia with Vertex Pharmaceuticals.
📈 The stock has a market capitalization of $4.53 billion and a price-to-earnings ratio of -7.55.
Bullish Signals
Major institutions added or initiated positions in CRISPR Therapeutics.
ARK increased stake 7.5% to 10.5M shares valued at $551.78M.
State Street lifted holdings 35.6% to 3.27M shares worth $159.08M.
Orbis Allan Gray raised stake 76.9% with 1.2M shares at $134.47M.
GSK initiated new position worth approximately $168.89 million.
Risk Factors
Insider sold 3,786 shares worth $210,577.
Holding reduced by 16.36%.
Bullish Signals
Major institutional investors including GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank have recently added to or initiated positions in CRISPR Therapeutics.
ARK Investment Management LLC significantly increased its stake by 7.5% in the fourth quarter, now holding over 10.5 million shares valued at $551.78 million.
State Street Corp lifted its holdings by 35.6% in the second quarter, increasing its position to 3.27 million shares worth $159.08 million.
Orbis Allan Gray Ltd raised its stake by 76.9% in the second quarter, acquiring an additional 1.2 million shares valued at $134.47 million.
GSK plc initiated a new position in CRISPR Therapeutics in the fourth quarter worth approximately $168.89 million.
Risk Factors
Insider Naimish Patel sold 3,786 shares for a total value of $210,577 to cover tax withholding obligations, reducing his personal holding by 16.36%.
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is the recent resignation of Chief Operating Officer Julianne Bruno, an event that has raised concerns among investors regarding internal stability and leadership continuity.
The stock currently exhibits high short interest, with over 20 million shares sold short representing approximately 25% of the public float. This heavy bearish positioning suggests that short-sellers are betting against the company's near-term prospects ahead of its upcoming earnings report scheduled for May 14, 2025. Analysts note that while the company has topped earnings estimates for three consecutive quarters, the high short interest creates a potential environment for significant volatility if results diverge from low expectations.
Despite the bearish sentiment, prominent investor Cathie Wood of Ark Invest maintains a bullish long-term view on gene editing technology. Although she recently trimmed her position by selling over $354,000 worth of shares, she still considers CRSP a potential performer that could outperform during an economic recession. The article highlights the company's strong balance sheet and its co-developed gene therapy, Casgevy (with Vertex Pharmaceuticals), as key assets that could drive a turnaround despite a lackluster rollout so far.
The stock currently trades at a low price-to-book ratio of 1.69x, which some analysts view as indicative of a deep-value opportunity rather than a high-growth stock. With low analyst expectations and a valuation that appears discounted relative to its potential, the article suggests that CRSP could be a dangerous name to short given its cash reserves and innovative pipeline. The upcoming earnings report is expected to be a critical catalyst that could trigger a significant price movement for the gene-editing innovator.
📉 Shares down 80% from 2021 highs and 8% year-to-date.
👤 Lost COO Julianne Bruno, raising leadership stability concerns.
🐻 Short interest exceeds 25% of the public float.
🏆 Beat earnings estimates for three consecutive quarters.
💰 Strong cash balance supports development despite losses.
📉 Shares of CRISPR Therapeutics (CRSP) are down nearly 8% year-to-date and over 80% from their 2021 all-time highs.
👤 The company recently lost its COO, Julianne Bruno, raising concerns about leadership stability among investors.
🐻 Short interest is high at over 20 million shares, representing approximately 25% of the public float.
📅 Upcoming quarterly earnings are scheduled for May 14, 2025, expected to cause significant market volatility.
🏆 CRSP has topped earnings estimates for three consecutive quarters despite a difficult stock trajectory.
💰 The company possesses a strong balance sheet with sufficient cash to absorb further losses during development.
💊 Casgevy, a gene therapy developed alongside Vertex Pharmaceuticals (VRTX), shows promise despite a slow rollout.
📉 Cathie Wood recently trimmed her position by selling over $354,000 worth of shares but remains bullish long-term.
📊 The stock trades at a low price-to-book ratio of 1.69x, suggesting potential deep-value characteristics.
🌧️ Ark Invest CEO Cathie Wood views CRSP as a name that could rise stronger than others during an economic recession.
Bullish Signals
Topped earnings estimates for three straight quarters.
Strong balance sheet with ample cash on hand.
Trades at low price-to-book ratio of 1.69x.
Potential outperformer during economic recession per Cathie Wood.
Casgevy shows significant promise in clinical trials.
Risk Factors
Shares down 8% YTD and 80% from 2021 highs.
COO Julianne Bruno resigned, raising stability concerns.
Short interest exceeds 25% of public float.
Steep losses with no needle-moving product updates.
Bullish Signals
The company has topped earnings estimates for three straight quarters, demonstrating consistent operational performance despite market headwinds.
CRISPR Therapeutics maintains a strong balance sheet with ample cash on hand to absorb losses and fund future development.
The stock trades at a low price-to-book ratio of 1.69x, which some analysts interpret as a deep-value opportunity rather than a growth failure.
Cathie Wood highlights CRSP as a potential outperformer that could rise stronger than peers during an economic recession.
Casgevy has demonstrated significant promise in clinical trials, offering a potential revenue driver once the rollout accelerates.
Risk Factors
Shares are down nearly 8% year-to-date and more than 80% from their 2021 all-time highs, indicating severe investor skepticism.
The untimely resignation of COO Julianne Bruno has raised red flags regarding internal stability and management continuity.
High short interest of over 25% of the public float suggests a dominant bearish sentiment that could pressure the stock price.
The company is characterized by steep losses and a lack of needle-moving updates on existing products, making valuation difficult.
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is the recent resignation of Chief Operating Officer Julianne Bruno, an event that has raised concerns among investors regarding internal stability and leadership continuity.
The stock currently exhibits high short interest, with over 20 million shares sold short representing approximately 25% of the public float. This heavy bearish positioning suggests that short-sellers are betting against the company's near-term prospects ahead of its upcoming earnings report scheduled for May 14, 2025. Analysts note that while the company has topped earnings estimates for three consecutive quarters, the high short interest creates a potential environment for significant volatility if results diverge from low expectations.
Despite the negative sentiment, prominent investor Cathie Wood maintains a bullish long-term view on gene editing technology. Although she recently trimmed her position by selling over $354,000 worth of shares, she still considers CRSP a potential performer that could outperform during an economic recession. The article highlights the company's strong balance sheet and its co-developed therapy, Casgevy (with Vertex Pharmaceuticals), as key assets that could drive a turnaround despite a lackluster rollout so far.
Valuation metrics suggest the stock may be undervalued relative to its growth potential, trading at 1.69 times price-to-book. With low analyst expectations and a deep-value profile, some observers view the current price of less than $39 per share as an opportunity rather than a risk. The consensus is that while the trajectory has been difficult, the combination of innovation, cash reserves, and potential for a short squeeze makes the stock dangerous to short.
📉 Shares down 80% from 2021 highs and 8% year-to-date.
👤 COO Julianne Bruno resigned earlier this month.
🐻 Short interest exceeds 20 million shares (25% float).
Citizens Jmp reaffirmed its market outperform rating on CRISPR Therapeutics (CRSP) with a $80 price target, joining a chorus of recent analyst activity including Truist Financial's strong-buy upgrade and Piper Sandler raising its target to $110. While some analysts like Sanford C. Bernstein maintained hold ratings, the aggregate sentiment remains moderately bullish with an average target price of $67.78.
The company recently reported Q1 earnings of $1.46 million in revenue against a loss of $1.28 per share, resulting in negative net margins and return on equity. Analysts currently forecast a full-year loss of $4.89 per share for the current fiscal year, reflecting the high-burn nature of its gene-editing R&D pipeline focused on ex vivo therapies.
Institutional ownership remains robust at 69.20%, with significant recent accumulation from major funds including ARK Investment Management LLC, State Street Corp, and GSK plc. Notably, insider Naimish Patel sold shares totaling $210,577 to cover tax withholding obligations related to equity vesting, a transaction that reduced his direct ownership by 16.36%.
📈 Citizens Jmp restated rating to market outperform with $80 target.
📊 Truist upgraded to strong-buy; Piper Sandler raised target to $110.
💰 Q1 revenue hit $1.46M despite $1.28 loss per share.
🔮 Analysts forecast full-year earnings of -$4.89 per share.
🏦 ARK Management increased stake by 7.5% to over $551M.
📈 Citizens Jmp restated its rating to market outperform with an $80 price target on CRSP.
📊 Truist Financial upgraded the stock to strong-buy while Piper Sandler raised its target to $110.
💰 Q1 revenue reached $1.46 million, though the company posted a loss of $1.28 per share.
🔮 Analysts predict full-year earnings of -$4.89 per share for the current fiscal year.
🏦 ARK Investment Management LLC increased its stake by 7.5% to own over $551 million in shares.
📉 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.
🧬 The company focuses on ex vivo gene-editing therapies for sickle cell disease and thalassemia.
🤝 CRISPR Therapeutics collaborates with Vertex Pharmaceuticals on its lead CTX001 program.
📊 Institutional ownership stands at 69.20% following recent additions by State Street and GSK.
Bullish Signals
Citizens Jmp reaffirmed market outperform rating with $80 price target.
Truist upgraded to strong-buy; Piper Sandler raised target to $110.
ARK added over $735 million in value to position.
Strong pipeline targets sickle cell disease and beta-thalassemia.
Risk Factors
Analysts forecast full-year loss of $4.89 per share.
Insider sold 3,786 shares worth $210,577 for taxes.
Bullish Signals
Citizens Jmp reaffirmed a market outperform rating with an $80 price target, signaling continued institutional confidence in the company's long-term prospects.
Truist Financial upgraded CRSP to a strong-buy rating, while Piper Sandler raised its price target from $105 to $110, indicating growing analyst optimism.
Major institutional investors including ARK Investment Management LLC, State Street Corp, and GSK plc have recently increased their positions, with ARK adding over $735 million in value.
The company maintains a strong pipeline of ex vivo gene-editing therapies targeting serious diseases like sickle cell disease and transfusion-dependent beta-thalassemia.
Risk Factors
Analysts forecast a full-year loss of $4.89 per share for the current fiscal year, highlighting the company's continued cash burn before commercialization milestones.
Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations, reducing his direct ownership by 16.36%.
CRISPR Therapeutics (NASDAQ:CRSP) received a mixed analyst outlook following a downgrade by Wall Street Zen to a 'sell' rating, which contrasts with recent upgrades from Piper Sandler and Truist Financial. The company maintains a consensus 'Moderate Buy' rating with an average price target of $67.78, though individual targets vary significantly among major institutions like Morgan Stanley and Citigroup.
Financially, the biopharmaceutical firm reported Q1 earnings of $1.28 per share on revenue of $1.46 million. The company continues to operate with negative net margins and a negative return on equity, while analysts forecast a loss of $4.89 per share for the current year.
Institutional ownership remains robust at 69.20%, with significant additions from GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank in recent quarters. However, insider Naimish Patel sold approximately $210,577 worth of shares to cover tax withholding obligations related to equity vesting.
📉 Wall Street Zen downgraded CRISPR Therapeutics from 'hold' to 'sell'.
📈 Piper Sandler raised price target to $110 and Truist upgraded to 'strong-buy'.
💰 Q1 earnings hit $1.28 per share on $1.46 million revenue.
🏢 Institutional ownership is 69.20% with ARK and GSK increasing stakes.
👤 Insider Naimish Patel sold 3,786 shares for tax obligations.
📉 Wall Street Zen downgraded CRISPR Therapeutics from 'hold' to 'sell', creating a divergence in analyst sentiment.
📈 Piper Sandler raised its price target to $110.00 and Truist Financial upgraded the stock to 'strong-buy'.
💰 The company reported Q1 earnings of $1.28 per share on revenue of $1.46 million.
📉 Analysts forecast a loss of $4.89 per share for the current fiscal year.
🏢 Institutional ownership stands at 69.20% with major funds like ARK Investment Management and GSK increasing stakes.
👤 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.
Bullish Signals
Major institutions like GSK and State Street increased holdings.
Piper Sandler set $110.00 price target with overweight rating.
Truist Financial upgraded stock to strong-buy rating.
MarketBeat consensus Moderate Buy with $67.78 average target.
Risk Factors
Wall Street Zen downgraded stock to 'sell' rating.
Negative net margins of -13,856.54% and ROE of -25.66%.
Analysts forecast $4.89 loss per share for current year.
Bullish Signals
Major institutional investors including GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank have recently added new positions or increased holdings in the stock.
Piper Sandler restated an 'overweight' rating with a price target of $110.00, while Truist Financial upgraded the stock to a 'strong-buy' rating.
The company maintains a consensus 'Moderate Buy' rating from MarketBeat with an average analyst price target of $67.78.
Risk Factors
Wall Street Zen downgraded the stock from a 'hold' to a 'sell' rating, indicating bearish sentiment from at least one major analyst.
The company reported negative net margins of -13,856.54% and a negative return on equity of -25.66% for the quarter.
Analysts forecast a loss of $4.89 per share for the current year, suggesting continued financial losses in the near term.
Crispr Therapeutics (CRSP) received FDA pediatric approval for Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia. This regulatory milestone expands the company's addressable market and reinforces its leadership in CRISPR/Cas9 technology, despite previous challenges with complex treatment logistics and high costs associated with the therapy.
Following the announcement, CRSP stock surged over 8% to reach a four-month high of $60 per share, pushing the market capitalization to approximately $5.79 billion. The approval is viewed as a significant catalyst for accelerated revenue growth, driven by an expanded patient pool and technical advancements that could drive the stock price toward historic highs.
Beyond Casgevy, CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases. These initiatives aim to simplify gene therapy applications and further expand the company's therapeutic reach, positioning it for continued strategic growth in the gene editing sector.
🏥 FDA pediatric approval expands Casgevy market for sickle cell and beta-thalassemia.
📈 Stock surged 8% to $60/share on regulatory win.
💰 Market cap hit $5.79 billion reflecting investor optimism.
🔬 Robust pipeline includes cardiovascular and autoimmune disease programs.
⚠️ High costs and complex protocols hinder commercial uptake.
🏥 CRISPR Therapeutics secured FDA pediatric approval for Casgevy, expanding its market potential for sickle cell disease and beta-thalassemia treatments.
📈 Stock price jumped over 8% to a four-month high of $60 per share following the regulatory win.
💰 Market capitalization reached $5.79 billion as investors reacted positively to the expanded addressable market.
🔬 The company maintains a robust pipeline including in-vivo and allogeneic programs for cardiovascular and autoimmune diseases.
⚠️ Commercial uptake remains challenging due to complex treatment protocols and high therapy costs.
🚀 Pediatric approval is expected to drive significant upside potential toward historic share price levels.
Bullish Signals
FDA pediatric approval expands addressable market.
Stock surged 8% to $60 four-month high.
Market cap reached $5.79 billion.
Revenue growth expectations accelerate.
Risk Factors
High costs and complex logistics slow Casgevy uptake.
Revenue relies heavily on Casgevy amid pipeline risks.
Bullish Signals
CRISPR Therapeutics received FDA pediatric approval for Casgevy, significantly expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing technology.
The stock surged over 8% to a four-month high of $60 per share, reflecting strong investor confidence in the company's commercial prospects following the regulatory milestone.
Market capitalization increased to $5.79 billion, validating the market's view that Casgevy's multibillion-dollar potential is being realized despite initial commercial hurdles.
The approval accelerates revenue growth expectations as the patient pool expands and technical advances simplify gene therapy applications for a broader demographic.
Risk Factors
Casgevy faces continued commercial headwinds due to complex treatment logistics and high costs, which have historically slowed initial uptake despite strong clinical efficacy.
The company's reliance on Casgevy as a primary revenue driver remains a concentration risk if broader pipeline programs in cardiovascular or autoimmune diseases face development delays.
Analysts have recently upgraded their consensus revenue and earnings-per-share (EPS) forecasts for CRISPR Therapeutics (CRSP), projecting year-over-year EPS growth ahead of the company's upcoming earnings report. This shift in expectations highlights growing confidence in the near-term revenue potential of gene-editing therapies, particularly those derived from the strategic partnership with Vertex Pharmaceuticals.
The article notes that while this optimism may sharpen focus on commercialization milestones and early revenue traction, significant risks remain. CRISPR Therapeutics continues to operate with a very small current revenue base of approximately US$4.10 million and faces substantial ongoing losses. The company's history of frequent equity raises keeps concerns about share dilution and future funding needs front and center for investors.
Despite these challenges, the stock has recently gained against a softer market, suggesting it may be undervalued relative to its long-term potential. Fair value estimates from the Simply Wall St community vary widely, ranging from US$68 to US$176 per share, reflecting divergent views on whether the company can successfully transition from promising science to a sustainable business model.
📈 Analysts raised revenue and EPS forecasts ahead of earnings.
💰 Company reports $4.1M revenue with significant operating losses.
🤝 Optimism driven by Vertex Pharmaceuticals partnership potential.
⚠️ Risks include share dilution from frequent equity raises.
🎯 Fair value estimates range from $68 to $176 per share.
📈 Analysts have raised consensus revenue and EPS forecasts for CRISPR Therapeutics ahead of its upcoming earnings report.
💰 The company currently reports a very small revenue base of approximately US$4.10 million while operating with sizeable losses.
🤝 Heightened optimism is specifically tied to the commercialization potential of the Vertex Pharmaceuticals partnership.
⚠️ Frequent equity raises and ongoing unprofitability keep risks regarding share dilution and funding needs prominent.
📉 Recent stock price gains against a softer market suggest investors may view the current valuation as potentially undervalued.
🎯 Fair value estimates from analysts vary significantly, ranging from US$68 to US$176 per share.
Bullish Signals
Analysts upgraded revenue and EPS forecasts.
Shares appreciated despite softer market.
Vertex partnership drives commercialization.
Risk Factors
Substantial losses with only US$4.10 million revenue.
Frequent equity raises risk share dilution.
Critical funding needed for business transition.
Bullish Signals
Analysts have upgraded revenue and EPS forecasts, indicating growing confidence in near-term gene-editing revenue potential.
The company's shares have recently appreciated against a softer broader market, suggesting positive investor sentiment.
Strategic partnership with Vertex Pharmaceuticals is viewed as a key driver for upcoming commercialization milestones.
Risk Factors
CRISPR Therapeutics continues to report substantial losses and maintains a very small revenue base of US$4.10 million.
The company has a history of frequent equity raises, creating ongoing risks related to share dilution for existing shareholders.
Significant funding needs remain a critical challenge as the company attempts to transition from science to a sustainable business.
CRISPR Therapeutics (NASDAQ:CRSP) saw its analyst rating upgraded to 'Hold' by Wall Street Zen, following a recent wave of mixed-to-positive sentiment from major institutions. Citigroup restated its rating to 'market outperform,' while Sanford C. Bernstein raised its price target to $56.00 and Evercore set an objective at $76.00. Conversely, Morgan Stanley maintained an 'equal weight' rating with a $60.00 target. The consensus average rating remains 'Moderate Buy' with a target price of $67.78, reflecting a generally positive but cautious outlook from the sell-side.
The company reported Q1 earnings on March 31st, posting a loss of $1.28 per share against minimal revenue of $1.46 million. Financial metrics showed a negative return on equity of -25.66% and a significant net margin contraction of -13,856.54%. Analysts currently anticipate the company will report an average annual loss of $4.89 per share for the current fiscal year, highlighting its continued pre-revenue or early-stage profitability challenges despite its technological advancements.
Institutional ownership remains robust at 69.20%, with notable increases in stakes from GSK plc, Orbis Allan Gray Ltd, State Street Corp, and ARK Investment Management LLC during the second and fourth quarters. However, insider Naimish Patel sold 3,786 shares worth approximately $210,577 to cover tax withholding obligations related to equity vesting, reducing his direct ownership by 16.36%. The company focuses on gene-editing therapies using its CRISPR/Cas9 platform, with lead program CTX001 targeting sickle cell disease and beta-thalassemia in collaboration with Vertex Pharmaceuticals.
📈 Wall Street Zen upgraded CRISPR Therapeutics to 'Hold'.
💰 Q1 loss hit $1.28/share on just $1.46M revenue.
🏦 Institutional ownership reached 69.20% with major additions.
🧬 Lead program CTX001 targets sickle cell disease.
📈 Wall Street Zen upgraded CRISPR Therapeutics to a 'Hold' rating, joining recent positive actions from Citigroup and Evercore.
🎯 Analyst consensus maintains a 'Moderate Buy' status with an average price target of $67.78.
💰 Q1 earnings showed a loss of $1.28 per share on revenue of only $1.46 million.
📉 The company reported a negative net margin of -13,856.54% and negative return on equity of -25.66%.
🔮 Analysts forecast an average annual loss of $4.89 per share for the current fiscal year.
🏦 Institutional ownership stands at 69.20%, with significant additions from ARK Investment Management and State Street Corp.
📉 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.
🧬 Lead program CTX001 targets sickle cell disease and beta-thalassemia in collaboration with Vertex Pharmaceuticals.
🔬 The company utilizes proprietary CRISPR/Cas9 technology for ex vivo and in vivo gene-editing therapies.
Bullish Signals
Wall Street Zen upgraded stock to Hold from Sell.
Citigroup restated rating to market outperform.
Sanford Bernstein raised price target to $56.00.
Evercore issued outperform rating with $76.00 objective.
Institutional investors increased holdings in recent quarters.
Risk Factors
Q1 loss of $1.28 per share indicates ongoing profitability challenges.
Minimal revenue of $1.46 million suggests limited commercial scale.
Negative ROE of -25.66% and massive net margin contraction of -13,856.54%.
Analysts expect continued losses with average EPS of -$4.89 for the year.
Insider sold 3,786 shares worth $210,577, reducing ownership by 16.36%.
Bullish Signals
Wall Street Zen upgraded the stock to a 'Hold' rating, signaling improved sentiment from a previous 'Sell' classification.
Citigroup restated its rating to 'market outperform,' indicating confidence in the company's long-term prospects.
Sanford C. Bernstein increased its price target to $56.00 and maintained a 'market perform' rating.
Evercore issued an 'outperform' rating with a high price objective of $76.00.
Major institutional investors including ARK Investment Management, State Street Corp, and GSK plc have increased their holdings in the second or fourth quarter.
The stock maintains a consensus 'Moderate Buy' rating from MarketBeat with a target price of $67.78.
Risk Factors
The company reported a significant loss of $1.28 per share for the first quarter, indicating ongoing profitability challenges.
Revenue was minimal at only $1.46 million for the quarter, suggesting limited commercial scale at this stage.
Financial metrics include a negative return on equity of -25.66% and a massive net margin contraction of -13,856.54%.
Analysts anticipate continued losses with an average expected EPS of -$4.89 for the current fiscal year.
Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax obligations, representing a 16.36% reduction in his direct ownership.
Simply Wall St analysis suggests CRISPR Therapeutics (CRSP) shares are trading at US$54.09, representing a significant discount to its estimated fair value of US$177.40 based on a discounted cash flow (DCF) model projecting future cash flows.
The stock has demonstrated solid short-term momentum with a 7-day return of 8.61% and a 30-day return of 8.40%, contributing to a one-year total shareholder return of 22.24%. However, the company currently reports ongoing losses of US$568.534 million and relies on the successful development of its early-stage pipeline.
While the DCF model indicates the stock is undervalued by approximately 69.5%, analyst price targets present a more cautious outlook, with an average target of US$83.52 implying only a 54% discount to current prices. The article highlights the divergence between high-growth cash flow expectations and near-term profitability concerns typical for clinical-stage biotech firms.
Investors are presented with a choice between trusting the higher DCF valuation driven by future revenue growth potential or the more conservative analyst consensus. The analysis notes that while the company focuses on gene editing medicines using its CRISPR/Cas9 platform, assumptions regarding trial data and regulatory milestones could quickly alter these underlying valuations.
📊 CRSP trades at $54, a 69.5% discount to $177 fair value.
📈 Stock gained 8.61% last week and 8.40% last month.
💰 Company reports $568.5M losses against only $4.1M revenue.
🔬 Valuation depends on future cash flows, not current profits.
⚠️ Success hinges on pipeline development and upcoming trial data.
📊 CRISPR Therapeutics (CRSP) is trading at US$54.09, which Simply Wall St's DCF model values as a 69.5% discount to a fair value of US$177.40.
📈 The stock has posted strong short-term performance with an 8.61% return over the last week and an 8.40% return over the last month.
💰 The company currently reports ongoing losses totaling US$568.534 million while generating revenue of US$4.1 million.
🔬 As a clinical-stage biotech, CRSP's valuation relies heavily on future cash flow projections rather than current net income or profitability.
📉 Analyst price targets are more conservative than the DCF model, with an average target of US$83.52 representing only a 54% discount to the current price.
⚠️ The valuation assumes successful development of the early-stage pipeline and favorable outcomes from upcoming trial data and regulatory milestones.
Bullish Signals
8.61% gain over past week and 8.40% over month.
Risk Factors
Substantial ongoing losses of US$568.534 million.
Low current revenue at only US$4.1 million.
Cautious analyst targets average US$83.52.
High valuation relies on early-stage pipeline success.
Bullish Signals
The stock exhibits strong short-term momentum with an 8.61% gain over the past week and an 8.40% gain over the past month.
Simply Wall St's discounted cash flow model estimates a fair value of US$177.40, implying the current price is significantly undervalued at a 69.5% discount.
The company has achieved a positive one-year total shareholder return of 22.24% despite being in a clinical-stage development phase.
Risk Factors
CRISPR Therapeutics reports substantial ongoing losses of US$568.534 million, indicating it is not yet profitable.
The company's current revenue is low at US$4.1 million, reflecting its early-stage commercial operations.
Analyst price targets are more cautious than the DCF model, with an average target of US$83.52 suggesting less optimism about immediate value realization.
The high valuation depends entirely on the successful development of an early-stage pipeline and favorable regulatory outcomes.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
